NanoRepro AGXTER:NN6 -2.54%51 Gross Margin % is 61.96% as of Jun. 2025, which is 2% above its 10-year median of 60.84. GuruFocus rates XTER:NN6 with a GF Score™ of 51/100 and a GF Value™ of €1.00 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 194 Medical Diagnostics & Research companies, NanoRepro AG ranks better than 62.89% on this metric.
NanoRepro AG gross margin has been in long-term decline. The average rate of decline per year is -5.7%.
The historical rank and industry rank for NanoRepro AG's Gross Margin % or its related term are showing as below:
XTER:NN6'
s Gross Margin % Range Over the Past 10 Years
Min: 31.43 Med: 60.84 Max: 108.97
Current: 61.1
During the past 13 years, the highestGross Margin % of NanoRepro AG was 108.97%. The lowest was 31.43%. And the median was 60.84%.
XTER:NN6's Gross Margin % is ranked better than 62.89% of 194
companies
in the Medical Diagnostics & Research industry
Industry Median: 51.14
vs XTER:NN6: 61.10
NanoRepro AG had a gross margin of 61.96% for the quarter that ended in Jun. 2025 => Durable competitive advantage
The 5-Year average Growth Rate of Gross Margin for NanoRepro AG was -5.70% per year.
NanoRepro AG (XTER:NN6) Gross Margin % Explanation
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
NanoRepro AG had a gross margin of 61.96% for the quarter that ended in Jun. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
NanoRepro AG Gross Margin % Related Terms
NanoRepro AG Gross Margin % Historical Data
* Premium members only.
The historical data trend for NanoRepro AG's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
XTER:NN6 vs TMO, DHR, IDXX: Gross Margin % Comparison
For the Diagnostics & Research subindustry, NanoRepro AG's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
NanoRepro AG Gross Margin % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, NanoRepro AG's Gross Margin % distribution charts can be found below:
* The bar in red indicates where NanoRepro AG's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
NanoRepro AG (XTER:NN6) has a Gross Margin % of 61.96% as of Jun. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on NanoRepro AG and its competitors. This is near median its historical median of 60.84. Over the past decade, NanoRepro AG's Gross Margin % has ranged from 31.43 to 108.97. According to the industry distribution chart, NanoRepro AG ranks #72 out of 194 companies in the Medical Diagnostics & Research industry, placing it in the top 37.1%.
Is NanoRepro AG's Gross Margin % too high?
NanoRepro AG's current Gross Margin % of 61.96% is near median its 10-year median of 60.84. Over the past 10 years, this metric has ranged from a low of 31.43 to a high of 108.97. The Medical Diagnostics & Research industry median Gross Margin % is 51.14. NanoRepro AG's value of 61.96% is 21.2% above this industry median. Based on the distribution chart, NanoRepro AG ranks #72 out of 194 companies in the Medical Diagnostics & Research industry, which is above the industry midpoint. Overall, NanoRepro AG has a GF Score™ of 51/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does NanoRepro AG's Gross Margin % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, NanoRepro AG ranks #72 out of 194 companies for Gross Margin %. This puts NanoRepro AG in the upper half of its industry. The industry median Gross Margin % is 51.14. NanoRepro AG's value of 61.96% is 21.2% above this benchmark. Historically, NanoRepro AG's own Gross Margin % has ranged from 31.43 to 108.97 over the past decade. While the company's 10-year median is 60.84 vs. the industry median of 51.14, NanoRepro AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Medical Diagnostics & Research company?
The median Gross Margin % among Medical Diagnostics & Research companies is 51.14, based on 194 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. NanoRepro AG's current Gross Margin % of 61.96% is 21.2% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on NanoRepro AG and its competitors. For the Medical Diagnostics & Research industry, the median Gross Margin % is 51.14 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. NanoRepro AG's current Gross Margin % is 61.96%, which is near median its own 10-year median of 60.84. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is NanoRepro AG stock overvalued right now?
Based on GuruFocus' analysis, NanoRepro AG (XTER:NN6) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.00, compared to a current price of €1.92 — trading 91.5% above its estimated fair value. The current Gross Margin % is 61.96%, which is near median its 10-year median of 60.84 and 21.2% above the Medical Diagnostics & Research industry median of 51.14. NanoRepro AG's overall GF Score™ is 51/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For NanoRepro AG (XTER:NN6), the current Gross Margin % is 61.96% as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is NanoRepro AG (XTER:NN6) Overvalued in 2026?
Based on GuruFocus' analysis, NanoRepro AG stock appears to be overvalued.
The current stock price of €1.92 is trading 91.5% above its estimated GF Value™ of €1.00.
GuruFocus considers NanoRepro AG to be Significantly Overvalued.
Key valuation signals for XTER:NN6:
Gross Margin %: 61.96% (near median its 10-year median of 60.84)
GF Value™: €1.00 vs. price of €1.92 (91.5% above fair value)
Industry Position: 21.2% above the Medical Diagnostics & Research median (#72 of 194)
No single metric tells the full story. See the XTER:NN6 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
NanoRepro AG is engaged in the development, manufacturing, and distribution of CE-certified rapid diagnostic tests (self-tests) and food supplements for both, home and professional use.
51GF Score
Get the complete analysis for XTER:NN6
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XTER:NN6 has been successfully added to your 
